PSMA-positive metastatic castration-resistant prostate cancer (MCRPC)
Clinical trials for PSMA-positive metastatic castration-resistant prostate cancer (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new PSMA-positive metastatic castration-resistant prostate cancer (MCRPC) trials appear
Sign up with your email to follow new studies for PSMA-positive metastatic castration-resistant prostate cancer (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can engineered immune cells take down treatment-resistant prostate cancer?
Cure Not yet recruitingThis trial tests ADI-212, a type of cell therapy made from donor immune cells engineered to recognize and attack prostate cancer cells that carry a protein called PSMA. The study enrolls adults with metastatic castration-resistant prostate cancer, a form of the disease that has s…
Matched conditions: PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
New Dual-Action therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis study tests a new approach for men with advanced prostate cancer that no longer responds to hormone therapy. It uses a special imaging agent to find cancer cells and a radioactive drug to destroy them. The goal is to see if the treatment is safe and shrinks tumors. About 49 …
Matched conditions: PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase 1/2 • Sponsor: Chengdu StarRay Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC